Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlovsky, Carolina, Vasconcelos Cordoba, Bianca, Sanchez, María Belén, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, Maria Josefina, Ventriglia, Maria Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Angel, de Labanca, Ana García, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, Jose, Sanchez Avalos, Julio Cesar, Cueto, Gerardo, Miranda, Silvia, Levy, Estrella Mariel, Bianchini, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148988/
https://www.ncbi.nlm.nih.gov/pubmed/37120577
http://dx.doi.org/10.1186/s13045-023-01440-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148988/
https://www.ncbi.nlm.nih.gov/pubmed/37120577
http://dx.doi.org/10.1186/s13045-023-01440-6

Ejemplares similares